Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.78 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 8/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.41 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.41 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL17184327 | 1.00 | SLC7A5 (0.78) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL4394463 | 1.00 | SLC7A5 (0.78) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL375261 | 1.00 | SLC7A5 (0.78) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL466382 | 1.00 | SLC7A5 (0.78) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL28161805 | 1.00 | SLC7A5 (0.78) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL17184328 | 1.00 | SLC7A5 (0.78) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| D-Leucine SCHEMBL11768667 | 1.00 | SLC7A5 (0.78) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL11305893 | 1.00 | SLC7A5 (0.78) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL466383 | 1.00 | SLC7A5 (0.78) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL2553000 | 0.96 | SLC7A5 (0.72) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501397-B2 | Helical peptidomimetics with enhanced activity | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1572076-A3 | HELICAL PEPTIDOMIMETICS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050272659-A1 | Helical peptidomimetics with enhanced activity | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1572076-A2 | HELICAL PEPTIDOMIMETICS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6846805-B2 | Helical peptidomimetics | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-6696488-B2 | (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030186877-A1 | Helical peptidomimetics | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-10-02 | — | — | US | disclosed |
| WO-2003068168-A2 | HELICAL PEPTIDOMIMETICS AND USE B-AMYLOID-ASSOCIATED DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| US-20020111365-A1 | Hydroxyethyl ureas as inhibitors of alzheimer's beta-amyloid production | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE A MASSACHUSETTS CORPORATION | 2002-08-15 | — | — | US | disclosed |
| WO-2002014264-A2 | (HYDROXYETHYL)UREAS AS INHIBITORS OF ALZHEIMER'S BETA-AMYLOID PRODUCTION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111365-A1 | Hydroxyethyl ureas as inhibitors of alzheimer's beta-amyloid production | BACE1, APP, BACE2 | SLC7A5 1979/4885SLC1A3 798/4885SLC1A2 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.